1.
Endocrinol Metab Clin North Am
; 52(3): 533-545, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37495343
RESUMO
Polycystic ovary syndrome (PCOS) affects around 10% of women in the reproductive age group and is characterized by ovulatory dysfunction, hyperandrogenism, and/or polycystic ovarian morphology. PCOS is highly associated with metabolic-associated fatty liver disease (MAFLD) as both diseases share common risk factors. At the time of diagnosis of PCOS, screening for MAFLD is necessary because most patients with MAFLD are asymptomatic. The importance of early detection of MAFLD in patients with PCOS is that a timely intervention in patients with steatosis or steatohepatitis can reduce the probability of liver disease progression.
Assuntos
Hiperandrogenismo , Resistência à Insulina , Hepatopatia Gordurosa não Alcoólica , Síndrome do Ovário Policístico , Humanos , Feminino , Síndrome do Ovário Policístico/complicações , Síndrome do Ovário Policístico/diagnóstico , Hepatopatia Gordurosa não Alcoólica/complicações , Hepatopatia Gordurosa não Alcoólica/diagnóstico , Fatores de Risco , Hiperandrogenismo/complicações
2.
Ann Hepatol
; 26: 100536, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34547479